Aktienanalyse wird geladen …
ZTS · NYSE · Pharmaceuticals · USA
70,27 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 9,47 Mrd. | 2,67 Mrd. | 6,02 $ | 443,84 Mio. | 1,2 Mio · 0,3 % | 12,2 Mio · 2,7 % | 71,8 % | 28,2 % | 5,14 $ | 0,19 $ | 2,03 $ |
| 2024 | 9,26 Mrd. | 2,49 Mrd. | 5,47 $ | 454,85 Mio. | 1,1 Mio · 0,2 % | 8,5 Mio · 1,9 % | 70,6 % | 26,9 % | 5,05 $ | 0,16 $ | 1,80 $ |
| 2023 | 8,54 Mrd. | 2,34 Mrd. | 5,07 $ | 462,27 Mio. | 0,9 Mio · 0,2 % | 9 Mio · 1,9 % | 70 % | 27,4 % | 3,51 $ | 0,13 $ | 1,56 $ |
| 2022 | 8,08 Mrd. | 2,11 Mrd. | 4,49 $ | 470,39 Mio. | 0,9 Mio · 0,2 % | 7,2 Mio · 1,5 % | 69,6 % | 26,2 % | 2,82 $ | 0,13 $ | 1,35 $ |
| 2021 | 7,78 Mrd. | 2,04 Mrd. | 4,27 $ | 476,72 Mio. | 0,8 Mio · 0,2 % | 2,7 Mio · 0,6 % | 70,4 % | 26,2 % | 3,64 $ | 0,12 $ | 1,08 $ |
| 2020 | 6,68 Mrd. | 1,64 Mrd. | 3,42 $ | 478,57 Mio. | 0,8 Mio · 0,2 % | 4,1 Mio · 0,8 % | 69,2 % | 24,5 % | 3,50 $ | 0,12 $ | 0,85 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,47 Mrd. | 691 Mio. | 1,65 $ | 417,7 Mio. | 28 % | 1,29 $ |
| Q1 2026 | 2,26 Mrd. | 601 Mio. | 1,42 $ | 422,4 Mio. | 26,6 % | 0,69 $ |
| Q4 2025 | 2,4 Mrd. | 624 Mio. | 1,41 $ | 438,6 Mio. | 26,1 % | 1,65 $ |
| Q3 2025 | 2,4 Mrd. | 721 Mio. | 1,63 $ | 443,2 Mio. | 30 % | 1,70 $ |
| Q2 2025 | 2,47 Mrd. | 726 Mio. | 1,63 $ | 445,5 Mio. | 29,4 % | 1,03 $ |
| Q1 2025 | 2,2 Mrd. | 602 Mio. | 1,34 $ | 448 Mio. | 27,4 % | 0,75 $ |
| Q4 2024 | 2,32 Mrd. | 581 Mio. | 1,31 $ | — | 25,1 % | 1,55 $ |
| Q3 2024 | 2,39 Mrd. | 682 Mio. | 1,50 $ | 453,5 Mio. | 28,6 % | 1,73 $ |
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
Companion Animal Diagnostic Market Forecasts Growth from $3.56B (2026) to $5.40B by 2031, Profiling IDEXX Laboratories & Zoetis
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock. Zoetis develops and markets products used by veterinarians, livestock producers, and pet owners across companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Its portfolio includes parasiticides, dermatology treatments, pain and sedation products, anti-infectives, diagnostic tools, genetic tests, and precision animal health solutions. The company also provides reference laboratory services, rapid tests, instruments, and other non-pharmaceutical offerings that support disease detection and animal care. Headquartered in Parsippany, New Jersey, Zoetis operates in the United States and international markets, serving a broad range of animal health needs across clinical, agricultural, and diagnostic settings.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest ZTS und jede andere Aktie unbegrenzt.